Original Paper

Is Combined Pretransplantation Seropositivity of Kidney Transplant Recipients for Cytomegalovirus Antigens (pp150 and pp28) a Predictor for Protection against Infection?
S. Essa^a, A. Pacsa^a, T. Said^b, M.R.N. Nampoory^b, R. Raghupathy^a, K.V. Johny^b, W. Al-Nakib^a, M. Al-Mosawy<sup>b

a</sup>Department of Microbiology, Faculty of Medicine, Kuwait University, and
^bHamad Al-Essa Organ Transplant Center, Ministry of Health, Kuwait

Address of Corresponding Author

Med Princ Pract 2008;17:66-70 (DOI: 10.1159/000109593)

  Key Words

• Kidney transplantation
• Cytomegalovirus infection
• Antibody responses
• Peptide antigens

  Abstract

Objective: This study was aimed at detecting antibodies to the antigens which may contribute to protection against cytomegalovirus (CMV) infection after organ transplantation. Materials and Methods: A total of 203 kidney transplant patients were enrolled in the study. Based on CMV antigenemia assay, 23 patients were antigen-positive and of the remaining 180 antigen-negative patients, 46 were selected as controls matched for age, gender and source of kidney. The 69 kidney recipients (KR) had CMV antibody due to previous infection and were followed up for a period of 6 months after transplantation for the development of active CMV infections by the antigenemia assay. Antibody responses to five CMV-related peptide antigens (pp65, gB, pp150, pp28 and pp38) were investigated by enzyme immunoassay and their presence was correlated with the results of the CMV antigenemia assay. Results: Of the five CMV-related peptide antigens, only gB antigen showed response to the antibody in 10/23 (43.5%) antigen-positive patients and 9/46 antigen-negative patients and the difference was statistically significant (p = 0.048). On the other hand, there was no significant difference in antibody responses between the antigen-positive and antigen-negative KR to the other four CMV peptide antigens (p > 0.05). However, among the antigen-positive KR there was only 1 patient who had antibodies to both pp150 and pp28 antigen, while among the antigen-negative KR, 22 of 46 (47.8%) had the antibodies (p < 0.001). Conclusion: The findings suggest that the combined presence of antibodies against the pp150 and pp28 antigens may indicate a lower risk of CMV reactivation after kidney transplantation.

Copyright © 2007 S. Karger AG, Basel

  References

1.

Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV: Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transpl 2000;14:136-138.

2.

Bolovan-Fritts CA, Mocarski ES, Wiedeman JA: Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 1999;1:394-398.

3.

Boppana SB, Britt WJ: Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 1995;171:1115-1121.

4.

Snydman DR: Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 1990;7:S839-S848.

5.

Meyers JD, Flournoy N, Thomas ED: Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-488.

6.

Rubin RH, Russell PS, Levin M, Cohen C: From the National Institutes of Health. Summary of a workshop on cytomegalovirus infections during organ transplantation. J Infect Dis 1979;139:728-734.

7.

Dummer JS, White LT, Ho M, Griffith BP, Hardesty RL, Bahnson HT: Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine. J Infect Dis 1985;152:1182-1191.

8.

Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV: Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001;184:1461-1464.

9.

Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JG: Human cytomegalovirus-specific cytotoxic T cells: relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 1988;168:919-931.

10.

Jonjic S, Pavic I, Plic B, Crnkovic I, Lucin P, Koszinowski UH: Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 1994;179:1713-1717.

11.

Essa S, Raghupathy R, Pacsa AS, El-Shazly A, Said T, Azizieh F: Th1-type cytokines production is decreased in kidney transplant recipients with active cytomegalovirus infection. J Med Virol 2000;60:223-229.

12.

Essa S, Pacsa AS, Al-Attiyah R, El-Shazly A, Raghupathy R, Said T: The use of flow cytometry for the detection of CMV-specific antigen (pp65) in leukocytes of kidney recipients. Clin Transpl 2000;14:147-151.

13.

Van Zanten J, De Leij L, Prop J, Harmsen MC, The TH: Human cytomegalovirus: a viral complication in transplantation. Clin Transpl 1998;12:145-158.

14.

Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, Hansen WP, Delmonico FL, Russell PS: Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981;305:308-314.

15.

Ljungman P, Niederwieser D, Pepe MS: CMV infection after marrow transplantation for aplastic anemia. Bone Marrow Transplant 1990;6:295-300.

16.

Meyers JD, Flournoy N, Thomas ED: Risk factors for CMV infection after human marrow transplantation. J Infect Dis 1986;153:478-488.

17.

Pass FR, Reynolds DW, Welchel JD, Diethelm AG, Alford CA: Impaired lymphocyte transformation response to CMV and phytohemagglutinin in recipients of renal transplant: association with antithymocyte globulin. J Infect Dis 1981;143:259-265.

18.

Landini MP, Guan MX, Jahn G, Lindenmaier W, Mach M, Ripalti A, Necker A, Lazzarotto T, Plachter B: Large-scale screening of human sera with cytomegalovirus recombinant antigens. J Clin Microbiol 1990;28:1375-1379.

19.

Goossens VJ, Vink C, Mullers W, Middeldorp JM, Bruggeman CA: Different profiles of cytomegalovirus RNA transcripts and anti-cytomegalovirus IgM antibodies in renal transplant recipients. J Clin Virol 2001;23:87-95.

20.

Muller TF, Gicklhorn D, Jungraithmayr T, Eickmann M, Lange H, Radsak K, Reschke M: Pattern and persistence of the epitope-specific IgM response against human cytomegalovirus in renal transplant patients. J Clin Virol 2002;24:45-56.

21.

Forman SJ, Zaia JA, Clark BR, Wright CL, Mills BJ, Pottathil R, Racklin BC, Gallagher MT, Welte K, Blume KG: A 64000 Da matrix protein of human cytomegalovirus induces in vitro immune responses similar to those of whole viral antigen. J Immunol 1985;134:3391-3395.

22.

Landini MP, Ripalti A, Sra K, Pouletty P: Human cytomegalovirus structural proteins: immune reaction against pp150 peptides. J Clin Microbiol 1991;29:1868-1872.

23.

Kraat YJ, Stals FS, Christiaans MHL, Lazzarotto T, Landini MP, Bruggeman CA: IgM antibody detection for pp38 (UL80a) and 150 (ppUL32) kDa proteins by immunoblotting: the earliest parameter for acute cytomegalovirus infection in renal transplant recipients. J Med Virol 1996;48:289-294.

24.

He H, Rinaldo CR, Morel PA: T cell proliferative responses to five human cytomegalovirus proteins in healthy seropositive individuals: implications for vaccine development. J Gen Virol 1995;76:1603-1610.

25.

Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ: Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;5:673-685.

26.

Beninga J, Kropff B, Mach M: Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol 1995;76:153-160.

27.

Alp NJ, Allport TD, VanZanten J, Rodgers B, Sissons JGP, Borysiewicz LK: Fine specificity of cellular immune responses in human to human cytomegalovirus immediate-early 1 protein. J Virol 1991;65:4812-4820.

28.

Curtsinger JM, Liu YN, Radeke R, Bryon MK, Fuad S, Bach FH, Gehrz RC: Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles. J Gen Virol 1994;75:301-307.

29.

Liu YN, Klaus A, Kari B, Stinski MF, Eckhardt J, Gehrz RC: The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B- and T-cell immune responses in humans. J Virol 1991;65:1644-1648.

30.

van der Bij W, Torensma R, van Son WJ, Anema J, Schirm J, Tegzess AM, The TH: Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes.J Med Virol 1988;25:179-188.

31.

Greijer AE, van de Crommert JM, Stevens SJ, Middeldorp JM: Molecular fine-specificity analysis of antibody responses to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnostic assays. J Clin Microbiol 1999;37:179-188.

32.

Jonjic S, Pavic I, Polic B, Crnkovic I, Lucin P, Koszinowski UH: Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 1994;179:1713-1717.

33.

Siadak MF, Kopecky K, Sullivan KM: Reduction in transplant-related complications in patients given intravenous immunoglobulin after allogeneic marrow transplantation. Clin Exp Immunol 1994;97(suppl 1):53-57.

34.

Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM: Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32.

35.

Reddehase MJ, Balthesen M, Rapp M, Jonjic S, Pavic I, Koszinowski UH: The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 1994;179:185-193.

36.

Schoppel K, Schmidt C, Einsele H, Hebart H, Mach M: Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis 1998;178:1233-1243.

37.

Schoppel K, Kropff B, Schmidt C, Vornhagen R, Mach M: The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 1997;175:533-544.

  Author Contacts

Sahar Essa
Department of Microbiology, Faculty of Medicine
Kuwait University, PO Box 24923
13110 Safat (Kuwait)
Tel. +965 498 6521, Fax +965 533 2719, E-Mail sahar@hsc.edu.kw

  Article Information

This research was supported by Kuwait University grant No. MI03/02.

Received: June 27, 2006
Revised: February 7, 2007
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 4, Number of References : 37

  Publication Details

Medical Principles and Practice (International Journal of the Kuwait University Health Sciences Centre)

Vol. 17, No. 1, Year 2008 (Cover Date: December 2007)

Journal Editor: Owunwanne, A. (Kuwait)
ISSN: 1011-7571 (print), 1423-0151 (Online)

For additional information: http://www.karger.com/MPP

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.